InvestInfoAI
FCPM III SERVICES B.V.

Q4 2025 · 13F-HR

FCPM III SERVICES B.V.holdings as filed

Filed 2026-02-17 · accession 0001193125-26-053151

$762.9M
Reported value
10
Positions
2025-12-31
Period end
View analyzed profile →PRO

The Brief · FCPM III SERVICES B.V. · Q4 2025

AI · grounded in 13F

FCPM III SERVICES B.V. established a new position in MPLT valued at $56.67M. The fund also opened a new position in CBIO for $19.9M and increased its holdings in VOR by 852.8% and RAPT by 432.6%. These additions offset the closure of its position in CATBUSD, which resulted in a $29.9M reduction.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$322.7M42.3%9,198,900CommonSHARED
26818M108DYNDYNE THERAPEUTICS INC$106.9M14.0%5,462,846CommonSHARED
29286M105ENGENE HOLDINGS INC$87.0M11.4%9,632,561CommonSHARED
75382E208RAPTRAPT THERAPEUTICS INC$62.1M8.14%1,833,333CommonSHARED
56565P103MPLTMAPLIGHT THERAPEUTICS INC$56.7M7.43%3,226,400CommonSHARED
929033207VORVOR BIOPHARMA INC$47.3M6.20%3,617,354CommonSHARED
76029N106REPLREPLIMUNE GROUP INC$27.3M3.58%2,808,368CommonSHARED
088786108BCYCBICYCLE THERAPEUTICS PLC$24.6M3.22%3,468,430CommonSHARED
G2545C104CBIOCRESCENT BIOPHARMA INC.$19.9M2.61%1,677,852CommonSHARED
29286M113ENGENE HOLDINGS INC$8.5M1.12%2,878,148CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.